Characteristics of patients and prognostic factors across treatment lines in metastatic colorectal cancer: an analysis from the Aide et Recherche en Cancérologie Digestive database

Bachet, Jean-Baptiste, de Gramont, Aimery, Raeisi, Morteza, Rakez, Manel, Goldberg, Richard M., Tebbutt, Niall C., Van Cutsem, Eric, Haller, Daniel G., Hecht, J. Randolph, Mayer, Robert J., Lichtman, Stuart M., Benson, Al B., Sobrero, Alberto F., Tabernero, Josep, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Zalcberg, John R., Grothey, Axel, Yoshino, Takayuki, André, Thierry, Shi, Qian and Chibaudel, Benoist 2025. Characteristics of patients and prognostic factors across treatment lines in metastatic colorectal cancer: an analysis from the Aide et Recherche en Cancérologie Digestive database. Journal of Clinical Oncology 10.1200/jco-24-01968

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB)

Abstract

PURPOSE Several lines of treatment can be used sequentially in patients with metastatic colorectal cancer. We investigated the evolution of patient/tumor characteristics and their prognostic impact across treatment lines to develop an overall prognostic score (OPS). PATIENTS AND METHODS Individual patient data from 48 randomized trials were analyzed. The end point was overall survival (from random assignment to death). Missing data were imputed. The complete data set was then separated into construction (80%) and validation sets (20%). The Cox's model was used to define risk groups for survival using the OPS. The discrimination capability was assessed in each treatment-line via bootstrapping to obtain optimism-corrected calibration and discrimination C-indices. Internal validation was done in the validation set. RESULTS A total of 37,560 patients (26,974 in first-line [1L], 7,693 in second-line [2L], and 2,893 in third-line [3L]) were analyzed. Some clinical, biological, and molecular characteristics of patients/tumors included in therapeutic trials evolve over the lines. Seven independent prognostic variables were retained in the final multivariate model common to all lines: Eastern Cooperative Oncology Group performance status, hemoglobin, platelet count, WBC/absolute neutrophil count ratio, lactate dehydrogenase, alkaline phosphatase, and the number of metastatic sites. The OPS was used to define four patient subgroups with significantly different prognoses in 1L, 2L, and 3L, separately, with adequate C-indices: 0.65, 0.66, and 0.69 in the construction set and 0.65, 0.66, and 0.68 in the validation set, respectively. The OPS was not predictive, with 3L drugs ( v placebo) or subsequent line (2L/1L or 3L/2L) extending survival in all prognostic groups. CONCLUSION The same prognostic model using practical variables can be used before all treatment lines. The OPS could better stratify patients in future clinical trials and help to therapeutic decision in routine practice.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Medicine
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Date of First Compliant Deposit:	2 June 2025
Date of Acceptance:	14 March 2025
Last Modified:	02 Jun 2025 11:45
URI:	https://orca.cardiff.ac.uk/id/eprint/178652

Actions (repository staff only)

Edit Item